CALC (CalciMedica) Notes Receivable: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CALC CalciMedica Inc CALC
30 GF Score
Price $0.68
! 2 Warning Signs
View Full Analysis

What is CalciMedica Notes Receivable?

CalciMedica CALC +0.79% 30 Notes Receivable is $0.00 Mil as of Jun. 2026. GuruFocus rates CALC with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

CalciMedica's Notes Receivable for the quarter that ended in Jun. 2026 was $0.00 Mil.

CalciMedica Notes Receivable Historical Data

* Premium members only.

The historical data trend for CalciMedica's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CalciMedica Notes Receivable Chart

CalciMedica Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

CalciMedica Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CALC
30GF Score
CalciMedica Inc CALC
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CalciMedica Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
CalciMedica (CALC) has a Notes Receivable of $0.00 Mil as of Jun. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on CalciMedica and its competitors.
Is CalciMedica's Notes Receivable too high?
CalciMedica's current Notes Receivable is $0.00 Mil. Overall, CalciMedica has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does CalciMedica's Notes Receivable compare to INTS and PHIO?
CalciMedica's Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on CalciMedica and its competitors. CalciMedica's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CalciMedica stock overvalued right now?
CalciMedica (CALC) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. CalciMedica's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For CalciMedica (CALC), the current Notes Receivable is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CalciMedica Business Description

Address 505 Coast Boulevard South, Suite 307, La Jolla, CA, USA, 92037
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
30GF Score

Get the complete analysis for CALC

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.68
Price